<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477840</url>
  </required_header>
  <id_info>
    <org_study_id>Kermanshah University</org_study_id>
    <nct_id>NCT01477840</nct_id>
  </id_info>
  <brief_title>Comparative of Effects of Sublingual Misoprostol and Infusion Oxytocin in Reduction of Bleeding at Cesarean</brief_title>
  <official_title>Phase 2-3 Study of Comparative of Effects of Sublingual Misoprostol and Infusion Oxytocin in Reduction of Blood Loss at Cesarean Deliveries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soudabeh Eshghi ali</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kermanshah University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kermanshah University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the effect of sublingual misoprostol is
      better than infusion oxytocin in reduction of blood loss at cesarean deliveries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 180 pregnant women with gestational age 37 weeks and over who underwent cesarean
      operation in Imam Reza hospital had elective or emergency procedure with incision in lower
      segment during one year recruitment. The patients were randomly assigned to undergo 200
      micrograms misoprostol sublingual or 400 micrograms and infusion 20 unit oxytocin after
      spinal anesthesia. Main outcome measures: The length of surgery, bleeding volume, the need
      for transfusion, fever, tachycardia, and hypotension.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative bleeding</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>During 48 hours after surgery measured every 3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing of pulse rate from base</measure>
    <time_frame>Before surgery &amp; intraoperative &amp; 6 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing of blood pressure</measure>
    <time_frame>Before surgery &amp; intraoperative &amp; 6 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>Before &amp; 6 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>Before &amp; 6 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Bleeding Intraoperative</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>Brand Name: Cytotec, Cyotec, Serial 022-00 , Code A02BB01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication of Cesarean Deliveries

          -  Elective or Emergency with Incision in Lower Segment in Women with

          -  Gestational Age more than 37 Weeks.

        Exclusion Criteria:

          -  Anemia

          -  Multiple Pregnancy

          -  Polyhydraminus

          -  Prolonged Labor

          -  Premature Rupture of Membrane and Patients had Previous History of Diabetes Mellitus

          -  Hypertension

          -  Cardiovascular Disease

          -  Coagulopathy Disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anisodowleh Nankali, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kermanshah University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anisodowleh Nankali, MD</last_name>
    <phone>98 831 4276310</phone>
    <email>anankali@kums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>KUMS Obstetrics &amp; Gynecology Department, Imam Reza Hospital</name>
      <address>
        <city>Kermanshah</city>
        <zip>67144-15333</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anisodowleh Nankali, MD</last_name>
      <phone>98 831 4276310</phone>
      <email>anankali@kums.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Soudabeh Eshghi Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.pubmed.com</url>
    <description>http://www.ncbi.nlm.nih.gov/pubmed?term=eftekhari%20n%2C%20doroodian%20m%2C%20lashkarizadeh%20r.</description>
  </link>
  <results_reference>
    <citation>Eftekhari N, Doroodian M, Lashkarizadeh R. The effect of sublingual misoprostol versus intravenous oxytocin in reducing bleeding after caesarean section. J Obstet Gynaecol. 2009 Oct;29(7):633-6. doi: 10.1080/01443610903061744.</citation>
    <PMID>19757270</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kermanshah University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Soudabeh Eshghi ali</investigator_full_name>
    <investigator_title>Obstetrics &amp; Gynecology Department</investigator_title>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Cesarean Delivery</keyword>
  <keyword>Blood Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

